All In Biotech

NDA 022030 · Pfizer

Toviaz

Fesoterodine Fumarate · Oral

Novel

Last checked: Nov 20, 2026Latest source record: Feb 28, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2008

Oct 31, 2008

Approved uses

2

Original approval plus efficacy supplements

Registered trials

59

16 Phase 3, 0 recruiting

FAERS reports

10,803

6,068 serious, 439 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 7, 2026.

Toviaz is indicated for the treatment of: • Overactive bladder (OAB) in adults with symptoms of urge urinary incontinence, urgency, and frequency. ( 1.1 ) • Neurogenic detrusor overactivity (NDO) in pediatric patients 6 years of age and older and weighing greater than 25 kg. ( 1.2 ) 1.1 Adult Overactive Bladder Toviaz is indicated for the treatment of overactive bladder (OAB) in adults with symptoms of urge urinary incontinence, urgency, and frequency. 1.2 Pediatric Neurogenic Detrusor Overactivity Toviaz is indicated for the treatment of neurogenic detrusor overactivity (NDO) in pediatric patients 6 years of age and older with a body weight greater than 25 kg.

Mechanism: Fesoterodine is a competitive muscarinic receptor antagonist. After oral administration, fesoterodine is rapidly and extensively hydrolyzed by nonspecific esterases to its active metabolite, 5-hydroxymethyl tolterodine, which is responsible for the antimuscarinic activity of fesoterodine. Muscarinic receptors play a role in contractions of urinary bladder smooth muscle. Inhibition of these receptors in the bladder is presumed to be the mechanism by which fesoterodine produces its effects.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • TOVIAZ · FESOTERODINE FUMARATE 4MG · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
  • TOVIAZ · FESOTERODINE FUMARATE 8MG · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Fesoterodine" as an intervention, any sponsor and status, largest first.

All 59 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective1,689
  • dry mouth823
  • fall535
  • off label use531
  • fatigue527
  • constipation508
  • urinary retention502
  • pain466
  • headache435
  • dizziness397
  • condition aggravated349
  • confusional state348

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20051
20081
200980
20101,035
2011544
2012904
20131,023
2014813
2015618
2016704
2017601
2018677
2019825
2020882
2021619
2022516
2023358
2024265
2025225
2026112

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Toviaz (Fesoterodine Fumarate)

2024 spending

$2.6M

Beneficiaries

1,675

6,052 claims

Per beneficiary

$1,574

$8.96 per unit

View as table
YearSpending
2020$180,987,271
2021$162,783,116
2022$107,715,372
2023$8,530,726
2024$2,636,887

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 119 on PubMed

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.